READY SIGNED
Getting ready to treat human patients with nanobody-targeted photodynamic therapy
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0READY project word cloud
Explore the words cloud of the READY project. It provides you a very rough idea of what is the project "READY" about.
Project "READY" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSITEIT UTRECHT
Organization address contact info |
| Coordinator Country | Netherlands [NL] |
| Total cost | 0 € |
| EC max contribution | 150˙000 € (0%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2019-PoC |
| Funding Scheme | ERC-POC-LS |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-01-01 to 2021-06-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSITEIT UTRECHT | NL (UTRECHT) | coordinator | 150˙000.00 |
Map
Project objective
Unfortunately, current cancer therapies often fail to cure patients, or are associated with severe side effects. Ideally, a therapy should locally eradicate cancer cells without damaging healthy tissue and should induce long term protection through activation of the immune system. Photodynamic therapy (PDT) is a treatment approach which can do both, through the local light activation of photosensitizers. However, current photosensitizers lack cancer specificity, which limits therapeutic efficacy and prolongs photosensitivity in patients. Recently, Dr. Oliveira has developed an improved version of targeted PDT that uses small antibody fragments, i.e. nanobodies, to target the photosensitizer to cancer cells. Nanobodies distribute homogenously, bind rapidly and specifically to cancer cells, and are quickly eliminated when unbound. Within the ERC StG KILLCANCER project, the team has been focusing on better understanding the mechanism of nanobody-targeted PDT, its potential to induce tumor regression in vivo, and its capacity to trigger the immune system for long term protection. Results indicate this treatment could lead to improved selectivity and reduced side effects, compared to conventional PDT and antibody-targeted PDT. The fundamental objective of this ERC PoC is to ascertain the technical and commercial viability of nanobody-targeted PDT for treatment of head and neck cancer. Within this project, the aims are to: 1. Humanize the lead nanobody, validate the results, and explore GMP production 2. Perform an IP landscape analysis and establish freedom-to-operate (FTO) 3. Execute an extensive market, competitor, and stakeholder analysis, and 4. Develop a detailed business plan based on this information to accurately guide commercialisation. Together, these steps will be essential for nanobody-targeted PDT to be ready for the translation to humans, so that cancer patients and society as a whole can benefit from this promising alternative treatment.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "READY" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "READY" are provided by the European Opendata Portal: CORDIS opendata.